Welcome to our dedicated page for ENvue Medical news (Ticker: FEED), a resource for investors and traders seeking the latest updates and insights on ENvue Medical stock.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company that reports on developments in enteral care, navigation systems, and acoustic-based therapeutic devices. Company news highlights its focus on intelligent, non-invasive solutions for enteral access and non-opioid pain management across clinical and home care settings, as well as updates on its technology platforms and corporate milestones.
News releases from ENvue cover topics such as the ENvue Navigation Platform, a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract, and its FDA 510(k) clearance for adult use. Updates may also describe initiatives to extend the platform, including exploratory programs that apply surface acoustic wave micro-vibration technology to address discomfort associated with indwelling nasogastric tubes.
Investors and clinicians can also find announcements about over-the-counter ENFit syringes designed for feeding and medication delivery, which ENvue describes as meeting ISO 80369-3 standards and supporting enteral delivery in both clinical and home environments. Additional news can relate to the company’s PainShield and UroShield acoustic-based therapeutic devices, which are intended to treat pain, reduce bacterial colonization, and disrupt biofilms in home or care settings.
Corporate news may include leadership changes, board appointments, and visibility events such as ringing the Nasdaq Opening Bell. By following ENvue Medical news on this page, readers can review company-issued information on technology progress, product introductions, platform integration efforts, and other disclosures that shape the company’s role in enteral care and non-invasive therapy.
ENvue Medical (NASDAQ: FEED) signed a nationwide distribution agreement with U-Deliver to supply its recently launched over-the-counter reusable ENFit Syringe line through non-acute channels. The syringes are available OTC via U-Deliver website, Amazon storefront, and wholesale in 2.5, 5, 10 and 60 mL sizes.
The ENFit syringes meet ISO 80369-3 standards and are designed for reuse up to seven days or 20 uses, aimed at improving enteral care access in home and long-term care settings.
ENvue Medical (NASDAQ: FEED; NASDAQ: NAOV) announced on January 21, 2026 the appointment of Marc Waldman as Vice President, Commercial to lead U.S. commercialization. Waldman brings 35+ years of medical device commercial leadership, GPO and IDN experience, and sector expertise in patient safety, enteral feeding and neonatal nutrition. He previously grew a neonatal enteral portfolio from $39M to $70M in 3.5 years and will focus on expanding ENvue’s current presence in 38 hospitals and accelerating revenue across the company’s enteral platform.
ENvue Medical (NASDAQ: FEED) announced on January 14, 2026 the launch of over-the-counter ENFit syringes for enteral feeding and medication delivery, available without a prescription. The syringes will be sold in institutional and consumer-friendly packaging and are anticipated to appear at certain online retailers including Amazon and durable medical equipment suppliers. Offered in 2.5 mL, 5 mL, 10 mL, and 60 mL sizes, the devices comply with ISO 80369-3 and are designed for reuse for up to seven days or 20 uses, aiming to support continuity of care across clinical and home settings.
ENvue Medical (NASDAQ: FEED) launched a development and integration program to evaluate its clinically validated NanoVibronix vibration technology for reducing pain and discomfort from indwelling nasogastric (NG) tubes.
The program builds on previously published, peer‑reviewed research showing surface acoustic wave micro‑vibration can reduce friction at the tube–tissue interface. The effort is exploratory and focused on technical feasibility, clinical pathway assessment, and regulatory and quality considerations, and does not represent a commercial product launch or regulatory clearance.
ENvue Medical (NASDAQ: FEED) will ring the Nasdaq Opening Bell at Nasdaq MarketSite in Times Square on Wednesday, January 14, 2026. The ceremony, led by Doron Besser, MD, CEO, will include company leadership, directors, employees, and key stakeholders. The event is scheduled for 8:30 A.M. – 9:45 A.M. ET at 151 West 43rd Street and will be available via live webcast.
This public ceremonial event highlights the company’s focus on non-invasive enteral access and non-opioid pain management technologies and offers a visibility opportunity for investors and stakeholders to observe leadership remarks and company representation.
ENvue Medical (NASDAQ: ENVB) announced on December 15, 2025 that David Johnson has been appointed Chairman of the Board. Johnson brings more than 30 years of healthcare leadership and board experience, including roles guiding Advanced Medical Balloons through acquisition and prior executive positions at ConvaTec and others.
The company said its 510(k) FDA-cleared feeding-tube placement system is in clinical use across 38 US hospitals, and management plans to increase hospital adoption in 2026 while pursuing additional 510(k) clearances to expand into neonatal and pediatric markets.
FAQ
What is the current stock price of ENvue Medical (FEED)?
What is the market cap of ENvue Medical (FEED)?
